NEW YORK — Cellectricon said on Tuesday that it has signed an agreement to use StressMarq Biosciences' reagents for its neurodegenerative research.
Mölndal, Sweden-based Cellectricon provides drug discovery services, with a focus on chronic pain and neurodegenerative disease. Among its areas of research is the spread of neurodegenerative disease-associated peptides, such as amyloid-beta peptides, tau, and alpha-synuclein, that characterizes Alzheimer's disease and Parkinson's disease.
Under the terms of the deal, British Columbia-based StressMarq will provide Cellectricon access to certain of its life science reagents including pre-formed fibrils of tau and alpha-synuclein, which can initiate protein aggregation and induce disease pathology in vitro and in vivo. Additional terms were not disclosed.
"A vital factor for enabling in vitro modelling of neuropathological processes is access to well-characterized reagents such as seed competent fibrils and filaments," Sebastian Illes, Cellectricon's director of central nervous system research, said in a statement. "Our collaboration with StressMarq … will enable us to access their high-quality portfolio of reagents for our services."